title: [Preventive effect and clinical significance of garlicin injection on mechanical ventilator-associated low respiratory tract deep-seated fungal infection].
abstract: OBJECTIVE
  To investigate the preventive effect and clinical significance of garlicin injection on ventilator-associated low respiratory tract deep-seated fungal infection (VRFI) as pneumonia.
  
  
  METHODS
  Retrospectively analysis on 147 patients underwent mechanical ventilation in our Intensive Care Unit (ICU) in recently 3 years was conducted. According to the garlicin injection administration was used or not, 79 patients with WVUH (West Virgina University Hospital) score > or = 25 points were selected and divided into the preventive group and the control group, and the differences in baseline conditions, incidence of VRFI and hospital outcome between the two groups were compared.
  
  
  RESULTS
  There was no significant difference between the two groups in baseline data as age, sex, APACHE II score, SAPS II score and WVUH score. But the incidence of VRFI in the preventive group was significantly lower than that in the control group (P<0.01). The relative risk in the latter was 2.06 (95% CI, 1.25-3.38). No significant difference was found between the two groups in hospital mortality (P>0.05).
  
  
  CONCLUSIONS
  Garlicin injection can effectively reduce the incidence of VRFI, and is inexpensive, it is an ideal prophylactic anti-fungal drug.
authors.affiliation: Shanghai Changzheng Hospital, Shanghai (200003). drguanjun@citiz.net
authors.forename: Jun
authors.initials: J
authors.lastname: Guan
authors.forename: Xing-yi
authors.initials: XY
authors.lastname: Yang
authors.forename: Liang
authors.initials: L
authors.lastname: Zhao
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000498:Allyl Compounds / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000627:therapeutic use; D003428:Cross Infection / Q000209:etiology / Q000517:prevention & control*; D004220:Disulfides / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000517:prevention & control*; D011014:Pneumonia / Q000382:microbiology / Q000517:prevention & control*; D012121:Respiration, Artificial / Q000009:adverse effects*; D012189:Retrospective Studies; D012307:Risk Factors
chemical_list: D000498:Allyl Compounds; D000935:Antifungal Agents; D004220:Disulfides; C028009:diallyl disulfide